Video Experimental Relacionado
Updated: May 6, 2026
12:50
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
6.0K
Comparación de la elegibilidad recomendada para la terapia con estatinas de prevención primaria basada en las
Neha J Pagidipati1, Ann Marie Navar1, Hillary Mulder1
1Duke Clinical Research Institute, Duke University, Durham, North Carolina.
JAMA
|April 19, 2017
Resumen
Las nuevas directrices estadounidenses para el tratamiento con estatinas en la prevención primaria pueden recomendar un menor número de individuos para el tratamiento en comparación con las directrices más antiguas de la ACC/AHA. Esto podría afectar a los adultos jóvenes con alto riesgo de enfermedad cardiovascular.
Área de la Ciencia:
- Medicina cardiovascular
- Cardiología preventiva
- Directrices de salud pública
Sus antecedentes:
- Las recomendaciones de las directrices para el tratamiento con estatinas en la prevención primaria muestran diferencias significativas.
- El Grupo de Trabajo de Servicios Preventivos de los Estados Unidos (USPSTF) ahora enfatiza la terapia basada en los factores de riesgo de enfermedad cardiovascular (ECV) y un riesgo global de ECV de 10 años o más.
Objetivo del estudio:
- Comparar la elegibilidad de los adultos estadounidenses para el tratamiento con estatinas de prevención primaria bajo las recomendaciones de 2016 de USPSTF frente a las pautas de 2013 del American College of Cardiology/American Heart Association (ACC/AHA).
Principales métodos:
- Utilizó datos de la Encuesta Nacional de Examen de Salud y Nutrición (NHANES, por sus siglas en inglés) (2009-2014) de una muestra representativa a nivel nacional de 3416 adultos estadounidenses de 40 a 75 años.
- Evaluación de la elegibilidad de las estatinas sobre la base de las recomendaciones de la USPSTF de 2016 y las directrices de colesterol de la ACC/AHA de 2013, excluyendo a las personas con ECV previa.
Principales resultados:
- La plena aplicación de las recomendaciones de la USPSTF daría lugar al inicio de la administración de estatinas en un 15,8% adicional de pacientes, en comparación con el 24,3% según las directrices de la ACC/AHA.
- Un grupo notable (8,9%) recomendado por el ACC/AHA pero no por el USPSTF incluía adultos más jóvenes (40-59) con alto riesgo de ECV a largo plazo (media >30%) y personas con diabetes.
Conclusiones:
- Las recomendaciones de la USPSTF de 2016 pueden dar lugar a que se recomiende a menos personas el tratamiento con estatinas de prevención primaria en comparación con las directrices de la ACC/AHA de 2013.
- Esta diferencia en las recomendaciones podría afectar particularmente a los adultos más jóvenes con un riesgo cardiovascular sustancial a largo plazo.
Videos de Conceptos Relacionados
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
618
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
618
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
275
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
275
01:26Coronary Artery Disease IV: Preventive Measures
893
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
893
01:26Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747